PRELUDE THERAPEUTICS INC Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
PRELUDE THERAPEUTICS INC (PRLD) had Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year of $1.50 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $1.50M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $2.24M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $734.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year $1.47M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.24M 10-Q · filed 2026-05-12 |
| 2025-09-30 | $734.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.47M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.09M 10-Q · filed 2025-05-06 |
| 2024-09-30 | $561.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.15M 10-Q · filed 2024-08-12 |
| 2021-09-30 | $459.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $702.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.05M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |